GNI Group Ltd. (2160.T)
- Previous Close
2,441.00 - Open
2,484.00 - Bid --
- Ask --
- Day's Range
2,437.00 - 2,514.00 - 52 Week Range
1,005.00 - 3,865.00 - Volume
625,800 - Avg. Volume
1,044,853 - Market Cap (intraday)
125.149B - Beta (5Y Monthly) 1.37
- PE Ratio (TTM)
15.15 - EPS (TTM)
165.66 - Earnings Date May 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4,100.00
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
www.gnipharma.comRelated News
Performance Overview: 2160.T
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2160.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2160.T
Valuation Measures
Market Cap
125.15B
Enterprise Value
105.64B
Trailing P/E
15.16
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.72
Price/Book (mrq)
3.70
Enterprise Value/Revenue
4.06
Enterprise Value/EBITDA
7.30
Financial Highlights
Profitability and Income Statement
Profit Margin
31.12%
Return on Assets (ttm)
5.85%
Return on Equity (ttm)
34.02%
Revenue (ttm)
26.01B
Net Income Avi to Common (ttm)
8.09B
Diluted EPS (ttm)
165.66
Balance Sheet and Cash Flow
Total Cash (mrq)
23.21B
Total Debt/Equity (mrq)
10.26%
Levered Free Cash Flow (ttm)
1.89B
Research Analysis: 2160.T
Company Insights: 2160.T
2160.T does not have Company Insights